Patents by Inventor Alberto FERNANDEZ-TEJADA

Alberto FERNANDEZ-TEJADA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230219991
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: March 8, 2023
    Publication date: July 13, 2023
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Publication number: 20230131867
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: September 19, 2022
    Publication date: April 27, 2023
    Inventors: David GIN, Michelle ADAMS, Kai DENG, Philip LIVINGSTON, Govindaswami RAGUPATHI, Eric CHEA, Alberto FERNANDEZ-TEJADA, Lars Ulrik NORDSTROEM, William WALKOWICZ, Jeffrey GARDNER, Derek TAN
  • Patent number: 11629162
    Abstract: A number of triterpene saponin variants with different modifications on their central glycosyl ester linkage are described. Also described are methods of making and method of using such triterpene saponin variants.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: April 18, 2023
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Derek S. Tan, David Y. Gin, William E. Walkowicz, Alberto Fernandez-Tejada, Govindaswami Ragupathi
  • Publication number: 20230026100
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 26, 2023
    Inventors: David SPRIGGS, Alberto FERNANDEZ-TEJADA, Dharmarao THAPI
  • Patent number: 11447515
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 20, 2022
    Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
  • Publication number: 20220275017
    Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 1, 2022
    Inventors: David Y. GIN, Eric K. CHEA, Alberto FERNANDEZ-TEJADA, Derek S. TAN, Jason S. LEWIS, Jeffrey R. GARDNER, NagaVaraKishore PILLARSETTY
  • Patent number: 11274116
    Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: March 15, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVarakishore Pillarsetty
  • Patent number: 11066480
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 20, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Spriggs, Alberto Fernandez-Tejada, Dharmarao Thapi
  • Publication number: 20210070796
    Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.
    Type: Application
    Filed: April 20, 2020
    Publication date: March 11, 2021
    Inventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVaraKishore Pillarsetty
  • Patent number: 10906926
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 2, 2021
    Assignees: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER
    Inventors: David Y. Gin, Eric Chea, Alberto Fernandez-Tejada, Jeffrey Gardner, Jason Lewis, Philip Livingston, J. Tyler Martin, Lars Nordstroem, Naga Vara Kishore Pillarsetty, Govind Ragupathi, Derek Tan
  • Publication number: 20210002316
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: August 27, 2020
    Publication date: January 7, 2021
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Publication number: 20200239509
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 30, 2020
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Patent number: 10626137
    Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: April 21, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVaraKishore Pillarsetty
  • Publication number: 20180327436
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 15, 2018
    Applicant: ADJUVANCE TECHNOLOGIES, INC.
    Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Publication number: 20180112008
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Application
    Filed: March 16, 2016
    Publication date: April 26, 2018
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David SPRIGGS, Alberto FERNANDEZ-TEJADA, Dharmarao THAPI
  • Publication number: 20170283450
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 5, 2017
    Inventors: David GIN, Michelle ADAMS, Kai DENG, Philip LIVINGSTON, Govindaswami RAGUPATHI, Eric CHEA, Alberto FERNANDEZ-TEJADA, Lars Ulrik NORDSTROEM, William WALKOWICZ, Jeffrey GARDNER, Derek TAN
  • Patent number: 9718850
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 1, 2017
    Assignee: MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
  • Publication number: 20170096444
    Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 6, 2017
    Inventors: David Y. GIN, Eric K. CHEA, Alberto FERNANDEZ-TEJADA, Derek S. TAN, Jason S. LEWIS, Jeffrey R. GARDNER, NagaVarakishore PILLARSETTY